D. Boral Capital analyst Jason Kolbert initiated coverage of Lineage Cell Therapeutics (LCTX) with a Buy rating and $3 price target Lineage is a clinical-stage biotechnology company that specializes in developing innovative cell therapies aimed at treating degenerative diseases, the analyst tells investors in a research note. The firm says the company has a partnership with Roche, focusing on the development and commercialization of OpRegen.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LCTX: